SPAC FTII signs amended merger with Longevity Biomedical; target ticker LBIO on Nasdaq

FutureTech II Acquisition Corp.

FTII entered into amended merger agreement with Longevity Biomedical on Aug 12, 2025; post-close entity to merge into PubCo (surviving entity).
Longevity will acquire Cerevast Medical and Aegeria Soft Tissue before closing, then merge with FTII's subsidiary.
Sponsor FutureTech II Partners consented to waiver allowing Aegeria to solicit alternative acquisition proposals.
PubCo common stock expected to list on Nasdaq under ticker "LBIO" at closing; no financial terms disclosed.
Closing subject to stockholder and regulatory approvals; no expected closing date provided.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.